607 related articles for article (PubMed ID: 34006584)
1. Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy.
Huang J; Liu D; Wang Y; Liu L; Li J; Yuan J; Jiang Z; Jiang Z; Hsiao WW; Liu H; Khan I; Xie Y; Wu J; Xie Y; Zhang Y; Fu Y; Liao J; Wang W; Lai H; Shi A; Cai J; Luo L; Li R; Yao X; Fan X; Wu Q; Liu Z; Yan P; Lu J; Yang M; Wang L; Cao Y; Wei H; Leung EL
Gut; 2022 Apr; 71(4):734-745. PubMed ID: 34006584
[TBL] [Abstract][Full Text] [Related]
2. Pectin supplement significantly enhanced the anti-PD-1 efficacy in tumor-bearing mice humanized with gut microbiota from patients with colorectal cancer.
Zhang SL; Mao YQ; Zhang ZY; Li ZM; Kong CY; Chen HL; Cai PR; Han B; Ye T; Wang LS
Theranostics; 2021; 11(9):4155-4170. PubMed ID: 33754054
[No Abstract] [Full Text] [Related]
3. Gut microbiome affects the response to immunotherapy in non-small cell lung cancer.
Ren S; Feng L; Liu H; Mao Y; Yu Z
Thorac Cancer; 2024 May; 15(14):1149-1163. PubMed ID: 38572783
[TBL] [Abstract][Full Text] [Related]
4. Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy.
Wang Y; Ma R; Liu F; Lee SA; Zhang L
Front Immunol; 2018; 9():374. PubMed ID: 29556232
[TBL] [Abstract][Full Text] [Related]
5. Fucoidan enhances the anti-tumor effect of anti-PD-1 immunotherapy by regulating gut microbiota.
Li H; Dong T; Tao M; Zhao H; Lan T; Yan S; Gong X; Hou Q; Ma X; Song Y
Food Funct; 2024 Apr; 15(7):3463-3478. PubMed ID: 38456333
[TBL] [Abstract][Full Text] [Related]
6. The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors.
Najafi S; Majidpoor J; Mortezaee K
Life Sci; 2022 Dec; 310():121138. PubMed ID: 36309224
[TBL] [Abstract][Full Text] [Related]
7. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
8. The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer.
Peng Z; Cheng S; Kou Y; Wang Z; Jin R; Hu H; Zhang X; Gong JF; Li J; Lu M; Wang X; Zhou J; Lu Z; Zhang Q; Tzeng DTW; Bi D; Tan Y; Shen L
Cancer Immunol Res; 2020 Oct; 8(10):1251-1261. PubMed ID: 32855157
[TBL] [Abstract][Full Text] [Related]
9. Commensal microbiota contributes to predicting the response to immune checkpoint inhibitors in non-small-cell lung cancer patients.
Zhang C; Wang J; Sun Z; Cao Y; Mu Z; Ji X
Cancer Sci; 2021 Aug; 112(8):3005-3017. PubMed ID: 34028936
[TBL] [Abstract][Full Text] [Related]
10. PD-L1-Targeted Radionuclide Therapy Combined with αPD-L1 Antibody Immunotherapy Synergistically Improves the Antitumor Effect.
Wen X; Zeng X; Cheng X; Zeng X; Liu J; Zhang Y; Li Y; Chen H; Huang J; Guo Z; Chen X; Zhang X
Mol Pharm; 2022 Oct; 19(10):3612-3622. PubMed ID: 35652897
[TBL] [Abstract][Full Text] [Related]
11. PD-1/PD-L1 blockade: Prospectives for immunotherapy in cancer and autoimmunity.
Hosseinzadeh R; Feizisani F; Shomali N; Abdelbasset WK; Hemmatzadeh M; Gholizadeh Navashenaq J; Jadidi-Niaragh F; Bokov DO; Janebifam M; Mohammadi H
IUBMB Life; 2021 Nov; 73(11):1293-1306. PubMed ID: 34538007
[TBL] [Abstract][Full Text] [Related]
12. Fluctuations in Gut Microbiome Composition During Immune Checkpoint Inhibitor Therapy.
Sarkar J; Cortes Gomez E; Oba T; Chen H; Dy GK; Segal BH; Ernstoff MS; Ito F
World J Oncol; 2023 Jun; 14(3):178-187. PubMed ID: 37350807
[TBL] [Abstract][Full Text] [Related]
13. Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors.
Nagato T; Lee YR; Harabuchi Y; Celis E
Clin Cancer Res; 2014 Mar; 20(5):1223-34. PubMed ID: 24389326
[TBL] [Abstract][Full Text] [Related]
14. Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies.
Sui H; Ma N; Wang Y; Li H; Liu X; Su Y; Yang J
J Immunol Res; 2018; 2018():6984948. PubMed ID: 30159341
[TBL] [Abstract][Full Text] [Related]
15. Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Non-Small Cell Lung Cancer.
Li JX; Huang JM; Jiang ZB; Li RZ; Sun A; Lai-Han Leung E; Yan PY
Integr Cancer Ther; 2019; 18():1534735419890020. PubMed ID: 31838881
[TBL] [Abstract][Full Text] [Related]
16. Integrin α
Chen H; Zhao L; Fu K; Lin Q; Wen X; Jacobson O; Sun L; Wu H; Zhang X; Guo Z; Lin Q; Chen X
Theranostics; 2019; 9(25):7948-7960. PubMed ID: 31695808
[TBL] [Abstract][Full Text] [Related]
17. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
[TBL] [Abstract][Full Text] [Related]
18. Programmed Cell Death-1: Programmed Cell Death-Ligand 1 Interaction Protects Human Cardiomyocytes Against T-Cell Mediated Inflammation and Apoptosis Response In Vitro.
Tay WT; Fang YH; Beh ST; Liu YW; Hsu LW; Yen CJ; Liu PY
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244307
[TBL] [Abstract][Full Text] [Related]
19. Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
Botticelli A; Cerbelli B; Lionetto L; Zizzari I; Salati M; Pisano A; Federica M; Simmaco M; Nuti M; Marchetti P
J Transl Med; 2018 Aug; 16(1):219. PubMed ID: 30081936
[TBL] [Abstract][Full Text] [Related]
20. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]